Charles Schwab Investment Management Inc. Trims Stock Position in Artivion, Inc. (NYSE:AORT)

Charles Schwab Investment Management Inc. lessened its stake in Artivion, Inc. (NYSE:AORT) by 0.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 349,849 shares of the company’s stock after selling 1,722 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.84% of Artivion worth $9,313,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of AORT. Perceptive Advisors LLC boosted its stake in shares of Artivion by 4.7% in the second quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock worth $71,658,000 after acquiring an additional 124,725 shares during the last quarter. First Eagle Investment Management LLC lifted its holdings in Artivion by 4.9% in the 2nd quarter. First Eagle Investment Management LLC now owns 598,148 shares of the company’s stock valued at $15,342,000 after purchasing an additional 27,906 shares in the last quarter. Quest Partners LLC lifted its holdings in Artivion by 2,481,700.0% in the 3rd quarter. Quest Partners LLC now owns 24,818 shares of the company’s stock valued at $661,000 after purchasing an additional 24,817 shares in the last quarter. Creative Planning boosted its stake in Artivion by 182.1% during the 3rd quarter. Creative Planning now owns 28,635 shares of the company’s stock worth $762,000 after purchasing an additional 18,486 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Artivion during the third quarter worth $450,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Insider Activity at Artivion

In related news, VP Andrew M. Green sold 7,618 shares of Artivion stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total value of $228,540.00. Following the completion of the transaction, the vice president now owns 33,503 shares in the company, valued at $1,005,090. The trade was a 18.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Amy Horton sold 12,430 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total transaction of $325,417.40. Following the completion of the sale, the chief accounting officer now directly owns 139,989 shares in the company, valued at approximately $3,664,912.02. This represents a 8.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 24,377 shares of company stock worth $682,356. Corporate insiders own 8.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on AORT. Needham & Company LLC restated a “buy” rating and issued a $34.00 price target on shares of Artivion in a research report on Monday. JMP Securities initiated coverage on Artivion in a report on Wednesday, October 23rd. They issued an “outperform” rating and a $33.00 target price for the company. Stifel Nicolaus lifted their price target on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, September 13th. Finally, Oppenheimer upped their price objective on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $31.80.

Artivion Stock Down 2.2 %

NYSE:AORT opened at $29.00 on Tuesday. Artivion, Inc. has a 52 week low of $16.48 and a 52 week high of $30.10. The stock’s fifty day moving average is $27.43 and its two-hundred day moving average is $26.07. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -1,450.00 and a beta of 1.75. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.